Jinhua (Jenny) Feng | Vice President, Head of CMC
Salubris Pharmaceuticals Co., Ltd

Jinhua (Jenny) Feng, Vice President, Head of CMC, Salubris Pharmaceuticals Co., Ltd

Dr. Jinhua Feng joined SalubrisBio in 2017 as the Director of Research and Development. She quickly rose to Vice President, taking charge of analytical and formulation development in-house and outsourcing GMP manufacturing and QC testing. Prior to joining SalubrisBio, Dr. Feng spent more than fifteen years at MedImmune/AstraZeneca, where she concentrated on analytical method development, product characterization and structure/function relationship of monoclonal antibodies and fusion proteins, including Synagis and motavizumab. Her contributions were critical for understanding stabilizing immunoglobulin, photo-induced oxidation, charge variants, and color change of drug products. During her tenure, she also assumed CMC analytical leadership for the production of multiple pipeline programs, including the first monoclonal antibody program transferred to China and the first bispecific ADC program in the company.
Dr. Feng completed her doctorate in Analytical Chemistry from Utah State University and her Post-Doctoral Fellowship at Nebraska Center for Mass Spectrometry.

Appearances:



Festival of Biologics Day 1 @ 15:00

Formulation development for monoclonal antibodies in early-stage CMC

  1. Formulation development tools with limited material available in early-stage CMC
  2. Effective and feasible screen strategy
  3. Thermo-stability versus solution stability
  4. Analytical testing strategy to support long-term stability study
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers